HMG

Female Fertility

Ovulation induction in anovulatory women: Scientific research has shown that the HMG peptide is effective for ovulation induction in anovulatory women, including those with PCOS. A study found that pulsatile HMG administration led to ovulation in 86% of cycles for women with prolonged anovulatory infertility, with a 40% pregnancy rate.

In women with PCOS, combining letrozole (2.5 mg) with HMG achieved an 85% ovulation rate, better endometrial receptivity, and increased mono-follicle development (3). The peptide has been approved for single follicle development in anovulation and multifollicular stimulation in ART protocols.

Controlled ovarian stimulation (COS) for IVF / ART: HMG peptide is widely used in controlled ovarian stimulation (COS) for IVF/ART to stimulate multiple follicles for higher oocyte retrieval. A meta-analysis found HMG achieved higher clinical pregnancy rates (RR ~1.22) compared to recombinant FSH in down-regulated IVF cycles (4).

Highly purified HMG (HP-HMG) further improved outcomes, showing significantly higher implantation (20% vs. 8.1%) and pregnancy rates (47.2% vs. 19.4%) compared to traditional HMG (5). Research has demonstrated that modern HMG formulations are effective, safe, and support successful ART outcomes (6).

Endometrial receptivity and follicle development: Research has shown that HMG peptide enhances endometrial receptivity and controlled follicle development. In a PCOS RCT, letrozole (2.5 mg) + HMG resulted in higher “type B” endometrial tissue (88.5% vs 69.0%) and monofollicular development (67.8% vs 46.0%) compared to a higher letrozole dose (3). Monitoring HMG cycles with serum estradiol (E2) and ultrasound is crucial, aiming for an E2 window of ≥1000 pg/mL over 9-12 days, optimizing follicular growth and endometrial preparation for implantation (1).

Male Fertility

Induction of spermatogenesis in men with hypogonadotropic hypogonadism: Studies show that combining HMG peptide and hCG successfully helps men with hypogonadotropic hypogonadism produce sperm. This regimen increases testicular volume (from ~3.08 mL to ~8.92 mL), testosterone production, and secondary sexual characteristics (7).

In a study, 81.2% of patients showed testicular growth, and 2 achieved spermatogenesis (8). Compared to FSH + testosterone, hCG + HMG was superior in inducing and maintaining spermatogenesis, highlighting its role in restoring fertility while avoiding the suppressive effects of exogenous testosterone (9).

Benefit in idiopathic oligozoospermia: Research suggests that HMG peptide, combined with hCG, benefits men with idiopathic oligozoospermia, particularly those with medium-to-high inhibin B levels. A 2019 trial showed significant improvements in sperm concentration, motility, morphology, and total motile sperm count after three months of therapy, alongside reduced DNA fragmentation (10).

Earlier studies reported pregnancies in the treated group, despite no statistical differences in sperm parameters. These findings highlight hCG/HMG therapy’s potential in enhancing fertility in select oligozoospermic men.

Testicular development and testosterone production: Research has demonstrated that HMG peptide, often combined with hCG, effectively stimulates testicular growth and testosterone production in men with hypogonadotropic hypogonadism. Studies show significant increases in testicular volume, penile size, and intratesticular testosterone, promoting spermatogenic cell maturation (11).

Unlike traditional testosterone therapy, HMG avoids suppressing the hypothalamic-pituitary-gonadal axis, supporting fertility while normalizing androgen levels. This treatment is highly effective in inducing pubertal development and restoring reproductive function in affected individuals (9).

Buy HMG Pre-Mixed Peptide Pen for research purposes from Peptide Works. Each 75 IU cartridge can be purchased individually or as part of a complete kit that includes a reusable pen, needle tips, and a carry case for convenient and precise preparation.